Page 22 - Read Online

Carciotto et al. Vessel Plus 2024;8:33 https://dx.doi.org/10.20517/2574-1209.2024.01 Page 13 of 13

22. Piccolo R, Simonetti F, Avvedimento M, et al. Ticagrelor 60 versus 90 mg in elderly ACS patients undergoing PCI: a randomized,
crossover trial. Eur Heart J 2024:pvae054. DOI
23. Galli M, Franchi F, Rollini F, Angiolillo DJ. Role of platelet function and genetic testing in patients undergoing percutaneous coronary
intervention. Trends Cardiovasc Med 2023;33:133-8. DOI PubMed
24. Gurbel PA, Tantry US, Shuldiner AR, Kereiakes DJ. Genotyping. J Am Coll Cardiol 2010;56:112-6. DOI PubMed
25. Capodanno D, Angiolillo DJ, Lennon RJ, et al. ABCD-GENE score and clinical outcomes following percutaneous coronary
intervention: insights from the TAILOR-PCI Trial. J Am Heart Assoc 2022;11:e024156. DOI PubMed PMC
26. Cayla G, Cuisset T, Silvain J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute
coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. The Lancet
2016;388:2015-22. DOI
27. Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome
undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. The Lancet
2017;390:1747-57. DOI PubMed
28. Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for Oral P2Y 12 inhibitors in primary PCI. N Engl J Med
2019;381:1621-31. DOI PubMed
29. Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary
intervention: a systematic review and meta-analysis. The Lancet 2021;397:1470-83. DOI
30. Galli M, Benenati S, Franchi F, et al. Comparative effects of guided versus potent P2Y12 inhibitor therapy in acute coronary
syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. Eur Heart J 2022;43:959-67. DOI PubMed PMC
31. De Luca G, Damen SA, Camaro C, et al. Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients
with acute coronary syndrome treated with a new-generation stent (REDUCE trial). EuroIntervention 2019;15:e990-8. DOI PubMed
32. Hahn JY, Song YB, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention
in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. The Lancet
2018;391:1274-84. DOI PubMed
33. Kedhi E, Fabris E, Van Der Ent M, et al. Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in
ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial. BMJ 2018:k3793. DOI PubMed
PMC
34. Costa F, Montalto C, Branca M, et al. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk:
a meta-analysis of randomized trials. Eur Heart J 2023;44:954-68. DOI
35. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation. Eur Heart J 2021;42:1289-367. DOI
36. Capodanno D, Baber U, Bhatt DL, et al. P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nat
Rev Cardiol 2022;19:829-44. DOI PubMed
37. Galli M, Capodanno D, Andreotti F, Crea F, Angiolillo DJ. Safety and efficacy of P2Y 12 inhibitor monotherapy in patients
undergoing percutaneous coronary interventions. Expert Opin Drug Saf 2021;20:9-21. DOI PubMed
38. Watanabe H, Morimoto T, Natsuaki M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy
with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: The STOPDAPT-2 ACS randomized clinical
trial. JAMA Cardiol 2022;7:407. DOI PubMed PMC
39. Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular
events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 2020;323:2407. DOI PubMed PMC
40. Hong SJ, Lee SJ, Suh Y, et al. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome:
the T-PASS randomized noninferiority trial. Circulation 2024;149:562-73. DOI
41. De Caterina R, Agewall S, Andreotti F, et al. Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing
coronary stenting should be limited to 1 week. Eur Heart J 2022;43:3512-27. DOI PubMed
42. Laudani C, Greco A, Occhipinti G, et al. Short duration of DAPT versus de-escalation after percutaneous coronary intervention for
acute coronary syndromes. JACC Cardiovasc Interv 2022;15:268-77. DOI PubMed
43. Kuno T, Watanabe A, Shoji S, et al. Short-term DAPT and DAPT de-escalation strategies for patients with acute coronary syndromes:
a systematic review and network meta-analysis. Circ Cardiovasc Interv 2023;16:e013242. DOI PubMed
44. De Filippo O, Piroli F, Bruno F, et al. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after
percutaneous coronary intervention: a systematic review and network meta-analysis. BMJ Evid-Based Med 2024;29:171-86. DOI
PubMed
45. Costa F, Van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing
stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets
from clinical trials. The Lancet 2017;389:1025-34. DOI